Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

World Bank Contributes Millions To New Indian Anti-Malaria Effort

This article was originally published in PharmAsia News

Executive Summary

The World Bank has earmarked $520.8 million to help India combat several fatal diseases, particularly malaria. The program is the body's largest such project and includes funds for treating more than 100 million Indians who, on average get malaria at the rate of more than 2 million a year. The funds also are to cover prevention services. The bank noted that falciparum malaria, an often-fatal severe form, has been on the rise in the country because of increased resistance to chloroquine, the primary malaria drug. The funds are intended to provide access to a new highly effective drug regimen for malaria. (Click here for more

You may also be interested in...



Teligent Moves To Consolidate Shares To Stay Listed

Teligent has followed through with plans to condense its outstanding shares to raise their value and maintain a stock-exchange listing. Meanwhile, the company revealed a sizeable loss for the first quarter of this year, as it gave the latest on its warning letter-stricken facility in Buena, New Jersey.

WHO Prequalifies Celltrion’s Rituximab

Celltrion's Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the World Health Organization.

Medac Will Market Fresenius Kabi’s Adalimumab In Germany

Fresenius Kabi’s Idacio biosimilar adalimumab rival to Humira will from the start of June be marketed in Germany by Medac, following a deal between the two companies.

UsernamePublicRestriction

Register

PL007508

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel